Business Context and Reporting Period
Supernus Pharmaceuticals, Inc. (SUPN) filed a Current Report on Form 8-K on November 4, 2024. The filing reports financial results for the third quarter ended September 30, 2024, and announces topline data from an open-label Phase 2a study of SPN-817 for treatment-resistant seizures.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release furnished as Exhibit 99.1, which is incorporated by reference but not detailed in the body of this 8-K.
Material Changes
The filing does not explicitly detail material changes versus the prior comparable period within the text provided. It references a press release for the full financial results and a conference call to discuss business and financial performance.
Guidance, Outlook, and Risks
- Outlook: The company announced topline data from the Phase 2a study of SPN-817, indicating progress in its clinical pipeline for treatment-resistant seizures.
- Management Commentary: A conference call was held on November 4, 2024, to present results. The webcast is archived on the company website.
- Risks: The filing includes standard forward-looking statement disclaimers, noting that future events are subject to risks and uncertainties detailed in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q3 2024 revenue, net loss, and cash position figures.
- Verify the specific topline data results for the SPN-817 Phase 2a study mentioned in the press release.
- Check the archived conference call webcast for management's commentary on the financial results and clinical trial implications.
- Consult the 2023 Form 10-K for detailed risk factors referenced in this filing.